AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on June 10. Analyst Asad Haider from Goldman Sachs maintained a Hold rating on the stock and has a $197.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Asad Haider has given his Hold rating due to a combination of factors that reflect both opportunities and challenges for AbbVie. The management’s discussion highlighted a positive outlook on near-term business trends, driven by strong execution momentum and impressive first-quarter results for 2025. However, the competitive dynamics in the immunology market, particularly in inflammatory bowel disease and the emerging opportunity in hidradenitis suppurativa, present uncertainties that could impact future growth.
Additionally, AbbVie’s strategic interests in expanding its neurology and obesity portfolios indicate potential for long-term growth, but these areas also come with inherent risks and require careful execution. The company’s engagement with policy discussions, particularly around drug pricing and trade negotiations, suggests a proactive approach, yet the outcomes of these discussions remain uncertain. These mixed factors contribute to the Hold rating, as they suggest a balanced view of potential risks and rewards for investors.
Haider covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Pfizer, and Eli Lilly & Co. According to TipRanks, Haider has an average return of 2.9% and a 70.00% success rate on recommended stocks.
In another report released on June 10, Citi also maintained a Hold rating on the stock with a $205.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue